Events - Pharvaris N.V.

Upcoming Events

Nov 30 - Dec 1, 2026

The British Society for Immunology Clinical Immunology Professional Network (BSI-CIPN) Conference 2026

Dec 2, 2026 10:00 AM EST

9th Annual Evercore Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Dec 4 - Dec 6, 2026

The Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) 2026 Congress

Dec 9 - Dec 10, 2026

8th Global Urticaria Forum (GUF) 2026

Past Events

Oct 23, 2024 from 10:00 AM to 11:30 AM EDT

Virtual Investor Event: Deucrictibant for the Prophylactic and On-Demand Treatment of Hereditary Angioedema (HAE) Attacks and Current HAE Market Dynamics and Unmet Need

Click for Webcast

Supporting Materials

Pharvaris Virtual Investor Day Presentation 1.4 MB

Oct 18 - Oct 20, 2024

73rd Annual Meeting of Japanese Society of Allergology

Supporting Materials

Efficacy and Safety of Oral Deucrictibant Immediate-Release Capsule in Hereditary Angioedema: RAPIDe-3 Phase 3 Clinical Trial Design 637.6 KB

Oct 4 - Oct 5, 2024

2024 Global Angioedema Forum – HAEi Global Leadership Workshop

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study (Oral) 1.4 MB

Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study (Poster) 678 KB

Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study (One-Pager) 407.1 KB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study (Oral) 1.5 MB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study (Poster) 285.9 KB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study (One-Pager) 616.9 KB

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 279.6 KB

Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 587.5 KB

Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs. Standard of Care in People Living with Hereditary Angioedema 434.3 KB

Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks 332.1 KB

Oct 2 - Oct 5, 2024

British Society Allergy and Clinical Immunology Conference (BSCAI 2024)

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial (Oral) 2.7 MB

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 234.4 KB

Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life in Patients With Hereditary Angioedema 717 KB

Relief and Resolution of Hereditary Angioedema Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release 626.4 KB

Sep 27 - Sep 29, 2024

World Allergy Congress 2024

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 879.5 KB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 735.2 KB

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 469.2 KB

Sep 26 - Sep 28, 2024

Deutscher Allergiekongress

Supporting Materials

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 1.6 MB

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 1.2 MB

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 1.2 MB

Characterizing Use of On-Demand Treatment Among People Living With Hereditary Angioedema in Germany 469.2 KB

Sep 13 - Sep 14, 2024

CIIC Fall 2024 Conference

Supporting Materials

Long-Term Safety and Efficacy of Prophylactic Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Hereditary Angioedema: Results of the CHAPTER-1 Open Label Extension Study 517.4 KB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 734.1 KB

Sep 5 - Sep 6, 2024

Bradykinin Symposium 2024

Supporting Materials

Bradykinin Challenge Model in Humanized Bradykinin B2 receptor Transgenic Rat 429 KB

Prophylactic Treatment with Deucrictibant Improves HAE Disease Control and HRQoL 337.3 KB

Long-Term Safety and Efficacy of Oral Deucrictibant for HAE Prophylaxis 183.8 KB

Treatment of HAE Attacks with Oral Deucrictibant: RAPIDe-2 Extension Results 622 KB

Prophylaxis of Hereditary Angioedema Attacks with Oral Deucrictibant: CHAPTER-1 Results 239.2 KB

Deucrictibant vs. Standard of Care in HAE: Propensity Score-Matched Analysis 186.3 KB

Clinical Trials Conformity with AURORA COS: a systematic literature review 156 KB

Cardiovascular safety of repeated oral administration of the B2 receptor antagonist deucrictibant 765.8 KB

The bradykinin challenge model translates across rat, monkey and human 1.5 MB

Deucrictibant inhibits carrageenan-induced edema in bradykinin B2 receptor transgenic rat 752.5 KB

A novel kinin biomarker assay for characterization of bradykinin-mediated disorders 905 KB

A HMWK capillary immunoblotting assay to characterize bradykinin-mediated disorders 865.2 KB

Sep 5, 2024 8:00 AM EDT

Pharvaris Corporate Update

Click for Webcast

Supporting Materials

Pharvaris Corporate Update Presentation 2 MB

Jun 28, 2024 9:00 AM EDT

2024 Annual General Meeting of Shareholders

Supporting Materials

Annual Report 2023 2.8 MB

Convening Notice and Agenda 58.2 KB

Voting Proxy 44.6 KB

Executed Minutes 474.2 KB

Pagination

First page
Previous page
…
Page 5
Page 6
Current page 7
Page 8
Page 9
…
Next page
Last page